Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2023 | The role of EEG as a biomarker in Alzheimer’s disease trials

Willem de Haan, MD, PhD, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, explores the utility of electroencephalography (EEG) as a biomarker in Alzheimer’s disease (AD) clinical trials. In clinical trials for potential AD drugs, the common desired outcome is an improvement in cognition. However, to comprehend the drug mechanisms driving this cognitive improvement, it’s essential to understand the changes in neuronal behavior that improve brain function, and this is where EEG plays a pivotal role. EEGs offer a direct assessment of neuronal and synaptic function, are readily available, user-friendly, and capable of detecting activity changes quickly, making them valuable for use in relatively short trials. This interview took place at the Clinical Trials on Alzheimer’s Disease (CTAD) congress 2023 in Boston.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Willem de Haan reports the following disclosures: Our EEG lab performs EEG analysis in pharmaceutical trials by Cognition Therapeutics, Vivoryon, Immunobrain, Treeway and CervoMed (for which I do not receive personal compensation).